Last mentioned: Mar 5, 2026
Operational Launch
The North Chicago facilities are expected to begin full-scale API production.
Evolysse Launch
Anticipated commercial rollout of the Evolysse dermal filler portfolio in the U.S.
Construction Start
Groundbreaking expected for the two new advanced manufacturing sites.
Earnings Release
Company reports Q4 beat and issues bullish 2026 revenue guidance.
Manufacturing Expansion
AbbVie announces $380M investment for North Chicago API facilities.
$100B Pledge
AbbVie commits to $100 billion in U.S. R&D and manufacturing over the next decade.
Q4 Fiscal Close
Evolus concludes its strongest fiscal year to date with record Jeuveau sales.
Evolus reported record Q4 2025 financial results, triggering a significant stock rally following a revenue beat and robust 2026 guidance. The company's performance underscores the resilience of the medical aesthetics market and the growing adoption of its flagship neurotoxin, Jeuveau.
AbbVie has announced a $380 million investment to expand its North Chicago manufacturing campus, marking the first major step in a $100 billion decade-long commitment to U.S. R&D. The initiative aims to localize active pharmaceutical ingredient production while integrating with the Trump administration's 'TrumpRx' program to lower drug costs.